English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
News
Childhood Cancer Day & Experts Review Paediatric CML Management
Each year on the 15th of February, the world recognises International Childhood Cancer Day. A day that raises awareness about childhood cancer, and expresses support to those affected and their families, as well as recognising the need for more research and access to better care.
This year, the International CML Foundation is proud to share our part in providing access to up-to-date knowledge in paediatric CML practices, in hopes to thus create better care for children and young adults with CML around the world. So without further ado, we’re pleased to officially announce the launch of Phase II of the iCMLf Knowledge Centre and our first Module: Paediatric CML.
Invitation: An iCMLf Conversation on Management of advanced phases of CML
January 2023 - Please save the date for the first iCMLf Conversation of 2023. Professor Mhairi Copland from the University of Glasgow will be our CML expert on Wednesday, February 22nd at 12 pm Central European Time.
During this live expert talk, we will focus on advanced phases of CML.
Professor Copland will share her expertise on the outcomes for blast phase CML and novel therapy options and will provide guidance on how to best treat your CML patients in advanced stages of CML.
There will be an interactive Q&A session at the end and all your questions, or cases are welcome for an open discussion.
Recognising excellence in CML. Nominate for the 2023 iCMLf Prizes
January 2023 - We hope you had a wonderful start into the New Year. In 2023, we continue with our tradition to recognise and reward excellence in the management and research of CML with the iCMLf Prizes.
Over the past years, we have honoured 33 scientists, clinicians and patient advocates with the three specific prizes. It has now turned into an impressive gallery of ‘Giants in CML’ – people who played a major role in advancing our understanding of the biology of CML and to improving the management of CML throughout their career.
Who would you like to see awarded the iCMLf prizes this year?
You can nominate colleagues and mentors for the three prizes below:
Seasons Greetings and Thank You for Your Support
As the year draws to a close we would like to express our appreciation for your continued interest, support and commitment to our work. 2022 has been a great success for the Foundation, with advancements in our CML research and expanding our ongoing commitment to the global CML community. Despite finding our way into a ‘new norm’ after the peak of the pandemic, together we rose to the challenges for one shared mission:
Improving the outcomes for people with CML globally
REMINDER: CML Highlights of ASH from Ravi Bhatia & Michael Mauro
December 2022 - Our last iCMLf Conversation of 2022 will take place this coming Monday.
Don’t forget to join us and Professors Ravi Bhatia and Michael Mauro for the clinical and biological updates on CML presented during ASH. This is the perfect opportunity for those who were unable to attend the meeting or for those who would like to get a recap of the CML data presented.
Date: Monday, December 19th at 2 pm Central European Time on Zoom.
Dial-in link for Zoom: https://us02web.zoom.us/j/81528835184
Read more about the program and other time zones…
iCMLf CANDID data - The impact of COVID-19 for patients with CML
‘The iCMLf CANDID study gave confidence for physicians worldwide that their patients with well controlled CML were not at greater risk from COVID-19 than the general population and no changes to CML therapy specifically due to SARS-CoV-2 infection were required.’
(Professor Jorge Cortes)
December 2022 - Through 2020-2022 the real-world data from the iCMLf CML and COVID-19 registry has helped to answer key questions on the impact of COVID-19 for patients with CML and continues to explore the impact of specific factors on risks and outcomes, as the pandemic continues.
The recent poster presentation at the American Society of Hematology meeting - "A Risk Model for CML Patients with COVID-19:Importance of Molecular Response in the Context of Age, Comorbidities and Country Income has the conclusion that “based on our personalized risk model, the risk of COVID-19-related mortality was higher in patients not in MMR”. This continues to illustrate the risk factors for people with CML and inform them and their physicians.
Below we summarise the key data that have been presented at major meetings from this important registry.
